News >

Cemiplimab Improves Survival in Frontline PD-L1–High NSCLC

Jason M. Broderick @jasoncology
Published: Monday, Apr 27, 2020

lung cancer
The PD-1 inhibitor cemiplimab (Libtayo) significantly improved overall survival (OS) versus platinum-based chemotherapy as a frontline treatment for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and a PD-L1 expression level of at least 50%, meeting the primary end point of a phase 3 trial.1 

Among 75 patients with metastatic CSCC, the ORR was 47% (95% CI, 35-59). The CR rate was 5% and the PR rate was 41%. The duration of response ranged from 3 months to over 15 months. Sixty percent of patients had a duration of response ≥6 months. In the 33 patients with locally advanced disease, the ORR was 49% (95% CI, 31-67), comprising all PRs. The duration of response ranged from 1 month to over 13 months. Sixty-three percent of patients had a duration of response ≥6 months.


  1. Phase 3 Trial Of Libtayo® (Cemiplimab) As Monotherapy For First-Line Advanced Non-Small Cell Lung Cancer Stopped Early Due To Highly Significant Improvement In Overall Survival. Published April 27, 2020. Accessed April 27, 2020.
  2. FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma. Published September 28, 2018. Accessed April 27, 2020

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication